vimarsana.com

Latest Breaking News On - Novel inhibitor - Page 3 : vimarsana.com

Artelo Biosciences Presents Positive Pre-Clinical Results of ART26 12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain

79 Indian-American including some South Asian Teens Named Nation s Top Scientists

79 Indian-American including some South Asian Teens Named Nation s Top Scientists
newsindiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsindiatimes.com Daily Mail and Mail on Sunday newspapers.

Multitude of Indian American High School Seniors Named Regeneron Scholars in Science Talent Search 2022

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema

Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE

Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema

Posted December 15th, 2020 for Novartis In Phase III KESTREL study , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.